
1. proc natl acad sci u a. 2020 jan 21;117(3):1678-1688. doi:
10.1073/pnas.1919035117. epub 2020 jan 8.

expansion, vivo-ex vivo cycling, genetic manipulation primary human
hepatocytes.

michailidis e(1), vercauteren k(1)(2), mancio-silva l(3), andrus l(1), jahan
c(1)(4), ricardo-lax i(1), zou c(1)(5), kabbani m(1), park p(1)(6), quirk c(1),
pyrgaki c(7), razooky b(1), verhoye l(2), zoluthkin i(8), lu wy(9), forbes sj(9),
chiriboga l(10), theise nd(10), herzog rw(8)(11), suemizu h(12), schneider wm(1),
shlomai a(13)(14), meuleman p(2), bhatia sn(3)(15)(16)(17)(18)(19)(20), rice
cm(21), de jong yp(21)(5).

author information: 
(1)laboratory virology infectious disease, rockefeller university, new
york, ny 10065.
(2)laboratory liver infectious diseases, ghent university, 9000 ghent,
belgium.
(3)institute medical engineering science, massachusetts institute of
technology, cambridge, 02142.
(4)département de biologie, ecole normale supérieure paris-saclay, université
paris-saclay, 9423 cachan, france.
(5)division gastroenterology hepatology, weill cornell medicine, new york,
ny 10065.
(6)department molecular virology, university hospital heidelberg, 69120
heidelberg, germany.
(7)bio-imaging resource center, rockefeller university, new york, ny 10065.
(8)division cellular molecular therapy, department pediatrics,
university florida college medicine, gainesville, fl 32607.
(9)medical research council centre regenerative medicine, university of
edinburgh, edinburgh eh16 4tj, united kingdom.
(10)department pathology, nyu langone health, new york, ny 10003.
(11)herman b. wells center pediatric research, indiana university,
indianapolis, 46202.
(12)laboratory animal research department, central institute experimental
animals, kawasaki 210-0821, japan.
(13)department medicine liver institute, rabin medical center,
belinson hospital, petach-tikva 49100, israel.
(14)department gastroenterology liver disease, sackler faculty medcine,
tel aviv university, tel aviv 64239, israel.
(15)broad institute mit harvard, cambridge, 02139.
(16)howard hughes medical institute, massachusetts institute technology,
cambridge, 02139.
(17)koch institute integrative cancer research, massachusetts institute of
technology, cambridge, 02139.
(18)department electrical engineering computer science, massachusetts
institute technology, cambridge, 02139.
(19)marble center cancer nanomedicine, massachusetts institute technology,
cambridge, 02139.
(20)department medicine, brigham women's hospital, boston, 02115.
(21)laboratory virology infectious disease, rockefeller university,
new york, ny 10065; ricec@rockefeller.edu ydj2001@med.cornell.edu.

primary human hepatocytes (phhs) essential tool modeling drug
metabolism liver disease. however, variable plating efficiencies, short
lifespan culture, resistance genetic manipulation limited their
use. here, show pyrrolizidine alkaloid retrorsine improves phh
repopulation chimeric mice average 10-fold rescues ability even 
poorly plateable donor hepatocytes provide cells subsequent ex vivo
cultures. mouse-passaged (mp) phh cultures overcome marked
donor-to-donor variability cryopreserved phh remain functional months 
as demonstrated metabolic assays infection hepatitis b virus and
plasmodium falciparum mpphh efficiently genetically modified culture,
mobilized, recultured spheroids retransplanted create highly
humanized mice carry genetically altered hepatocyte graft. together, these
advances provide flexible tools study human liver disease and
evaluation hepatocyte-targeted gene therapy approaches.

copyright © 2020 author(s). published pnas.

doi: 10.1073/pnas.1919035117 
pmcid: pmc6983380
pmid: 31915293  [indexed medline]

conflict interest statement: authors declare competing interest.

